NCT01976156View on ClinicalTrials.gov

The Gut-brain Axis: a Novel Target for Treating Behavioral Alterations in Obesity

NACompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

October 31, 2013

Primary Completion Date

October 31, 2017

Study Completion Date

October 31, 2017

Conditions
Neural Response in CaudateWeight Loss TrialImpulsivity
Interventions
DIETARY_SUPPLEMENT

PhosphoLean

PhosphoLean supplied by Cheminutra (White Bear Lake, MN). PhosphoLean® N-Oleoyl-PE + EGCG (NOPE + EGCG) is a proprietary phosphobioflavonic complex of N-oleoyl-phosphatidyl-ethanolamine (NOPE), which contains oleoyl ethanolamine (OEA) bound to phosphatidylethanolamine (PE), and epigallocatechin gallate (EGCG).

DIETARY_SUPPLEMENT

Placebo

Placebo consists of rice flour

Trial Locations (1)

06519

The John B Pierce Laboratory, New Haven

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Yale University

OTHER

NCT01976156 - The Gut-brain Axis: a Novel Target for Treating Behavioral Alterations in Obesity | Biotech Hunter | Biotech Hunter